Alexion's CEO Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha We are currently focused on applying the breakthrough innovation of Soliris and clinical development programs in four such disorders, acute humoral transplant rejection, STEC-HUS, neuromyelitis optica and myasthenia gravis. As we seek to maximize the ... |
